NEUROGENE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.88 USD | +1.94% |
|
+0.74% | +95.46% |
| Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
| Jun. 03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 248.5 | 491.7 | - | - |
| Enterprise Value (EV) 1 | 51.47 | 164.6 | -9.407 | 491.7 |
| P/E ratio | -2.49 x | -9.53 x | -10.3 x | -8.89 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | -0.99 x | -2.39 x | 0.12 x | -5.92 x |
| FCF Yield | -101% | -41.9% | 808% | -16.9% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 12,824 | 12,980 | - | - |
| Reference price 2 | 19.38 | 37.88 | 37.88 | 37.88 |
| Announcement Date | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -55.58 | -76.73 | -80.18 | -86.1 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -36.32 | -70.27 | -78.98 | - |
| Net income 1 | -55.19 | -36.32 | -66.52 | -78.59 | -88.15 |
| Net margin | - | - | - | - | - |
| EPS 2 | -10.58 | -7.798 | -3.973 | -3.666 | -4.260 |
| Free Cash Flow 1 | - | -51.74 | -69 | -76 | -83 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 11/8/23 | 3/18/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -14.73 | -18.78 | -19 | -19.3 | -19.65 | -19.95 | -20.25 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 2.383 | -16.92 | -17.3 | -17.76 | -18.28 | -18.74 | -19.21 |
| Net income 1 | 2.383 | -16.92 | -16.43 | -17.22 | -17.84 | -18.74 | -19.21 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | - | -1.000 | -0.9700 | -1.010 | -0.9200 | -1.045 | -1.040 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/18/24 | 5/10/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 197 | 327 | 501 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -51.7 | -69 | -76 | -83 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.32 | 1.5 | 1.1 | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 11/8/23 | 3/18/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
37.88
USD
Average target price
50.25
USD
Spread / Average Target
+32.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +95.46% | 492M | |
| +51.85% | 57.87B | |
| +41.53% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- NGNE Stock
- Financials Neurogene Inc.
